



ACARIX PRESENTS AT REDEYE LIFE SCIENCE DAY 2022

On November 24th at 14.50 CET Helen Ljungdahl Round, CEO of Acarix, will discuss the latest developments in the company in an in-depth interview, called InFocus.

The interview will be broadcasted live at <https://www.redeye.se/events/850947/redeye-life-science-day>, where you also will find the pre-recorded presentation. We encourage you to take this opportunity to ask questions directly to us via the form on the event page.

The recording will also be available after the event at <https://www.acarix.com/news/news>

For more information contact:

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Attachments

[Acarix presents at Redeye Life Science Day 2022](#)